ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical Infectious Diseases
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1660032
Assessing the Disease Burden of Lower Respiratory Infections Attributable to Particulate Matter Pollution: Trends from 1990 to 2021 and Projections for 2022-2050
Provisionally accepted- 1The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
- 2Universidade da Coruna, A Coruña, Spain
- 3South China Normal University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Particulate matter pollution (PMP) remains a leading risk factor for lower respiratory infections (LRIs) globally. However, the evolving contributions of household air pollution (HAP) versus ambient particulate matter pollution (APMP) across different development stages remain poorly characterized, hindering targeted intervention strategies. Methods: Using Global Burden of Disease 2021 data from 204 countries (1990-2021), we analyzed age-standardized mortality rates (ASMR) and disability-adjusted life years (DALY) for PMP-attributable LRIs, stratified by Socio-demographic Index (SDI), pollution source, and demographics. Temporal trends were assessed using Joinpoint regression, with projections to 2050. Results: In 2021, PMP was responsible for an estimated 651,238 (95% UI, 121,605-1076,503) deaths and 29,098,331(6,988,265-48,127,683) DALY from LRIs globally (ASMR: 8.68; ASDR: 420.09 per 100,000). Despite significant declines since 1990 (ASMR EAPC: - 2.44%), profound disparities persisted. Low-SDI regions experienced 23-fold higher mortality (ASMR: 31.28 per 100,000) than high-SDI regions (ASMR: 1.34 per 100,000), with slower improvement rates (EAPC: -3.41% vs -6.76% in high-middle SDI). A critical epidemiological transition emerged: APMP became predominant in high-income regions (approaching 100% of PMP burden), while HAP dominated in low-SDI settings (ASMR: 26.12 per 100,000). Regional heterogeneity was marked, with Central Sub-Saharan Africa bearing the highest HAP burden and minimal APMP improvement (EAPC: -0.24%). Children under 5 years of age group still accounted for the most PMP-related deaths, with the number decreasing from 851,458 (95% UI: 211,026 to 1,363,810) in 1990 to 201 ,078 (95% UI:61,817 to 337,232). In contrast, the APMP-related burden increased among adults aged 20 years and older. Strong inverse correlations between SDI and disease burden (r=-0.85, p<0.001) confirmed socioeconomic determinants. Projections suggest decelerating improvements post-2030. Conclusion: The global PMP reduction masks widening inequities between regions at different development stages. The divergent pollution profiles-HAP persistence in low-SDI regions versus APMP dominance in high-SDI regions-necessitate differentiated intervention strategies addressing both household energy transitions and ambient air quality regulations to achieve health equity by 2050.
Keywords: Global disease burden, Particulate matter pollution, Air Pollution, Lower Respiratory Infections, burden forecasting
Received: 05 Jul 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Geng, Wu, Tang, Zhu and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Dangmurenjiafu Geng, damrjab@163.com
Chang Du, duchang@m.scnu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.